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double-blind fashion 15 min before allergen challenge. Airway
calibre was monitored by FEV, for 4 h after the end of the challenge.
Salbutamol and salmeterol completely abolished the early phase of
bronchoconstriction in the first 120 min after challenge: the area
under the FEV1-time curve was inhibited by a mean of 90% for
salbutamol and 119% (net bronchodilatation) for salmeterol
(p < 0-005 vs placebo). However, in the second 120 min salbutamol
did not differ significantly from placebo while salmeterol provided
sustained bronchodilation throughout the 240 min. Neither
salbutamol nor salmeterol significantly altered LTE4 excretion in
the first 2 h after challenge but caused modest reductions in the
second 2 h collection (figure). There was no significant difference
between the two &bgr;z-agonists during either collection period. The
longer duration of action of salmeterol over salbutamol cannot be
explained in terms of any striking difference in effect on endogenous
cysteinyl-leukotriene generation. This also suggests that
02-adrenergic stimulation of the airway smooth muscle rather than
the mast cell may be functionally more important in vivo.
The issue of salmeterol’s putative anti-inflammatory effects in
vivo is important but is not resolved by either Twentyman’s study
or ours. This will require more direct observation of other features
of airway inflammation in asthma such as its effects on
inflammatory cell influx and cell activation markers in bronchial
biopsy specimens.
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SiR,&mdash;Your Dec 8 editorial misses the point of our study (Dec 1,
p 1338) when it states that "Bronchodilatation lasted up to 9 hours,
with protection against non-specific bronchial reactivity for up to 32
hours". Our study 1, in which no allergen was administered,
showed that bronchodilatation and functional antagonism of
bronchoconstriction did not extend to 32 hours after salmeterol
administration. Study 2 then showed that salmeterol protected
against the allergen-induced increase in bronchial responsiveness at
32 and 34 hours. This is an important point and implies that
salmeterol has an additional action distinct from bronchodilatation
and functional antagonism and can inhibit an effect of allergen that
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SIR,-Dr Twentyman and colleagues (Dec 1, p 1338), in their
paper on the long-acting p-agonist salmeterol in asthma, interpret
their data as showing a complete inhibition of both the early and late
responses after allergen challenge. They base this claim upon the
failure of antigen to cause significant bronchoconstriction when
compared with a prechallenge baseline. However, in administering
a potent and long-acting bronchodilator agent they have altered
baseline forced expiratory volume (FEV 1) and histamine
responsiveness such that the late response is only evident by
comparison with a saline challenge. If this comparison is made, a
late reaction is clearly demonstrated by changes in both airflow
obstruction and histamine challenge, which parallel those after
placebo. Salmeterol causes prolonged bronchodilation.1 The fall in
FEV1 seen 35-95 h after allergen challenge is therefore surprising
and provides further evidence that a late reponse is occurring. A
similar decline in PC2. histamine of 2-2 doubling dilutions is seen
between 1-5 and 7-5 h after challenge whereas there was apparently
no significant change after saline control.
It is likely that salmeterol is causing long-acting functional
antagonism of asthmatic responses because of its action at
&bgr;z-receptors. The parent compound, salbutamol, is not generally
considered to be an anti-inflammatory agent although it prevents
mast cell degranulation.3 The suggestion that salmeterol may have a
novel and as yet undetermined effect on the underlying
inflammatory process in asthma should be treated with some
caution. The claim that salmeterol has a potent anti-inflammatory
action could lead to a dangerous decrease in steroid prescribing.
Salmeterol administration was associated with an improvement
in FEV and PCzo histamine 32 h post allergen challenge. This is the
only tangible evidence of a true anti-inflammatory action. As
Twentyman et al point out, stimulation of the P-receptor depends
on the pharmacological profile of the drug used. Because of its
uniquely long duration of action, simple comparison of salmeterol
with conventional P-agonists is unjustified. Although modification
of the late phase response may occur, it is misleading to claim its
complete inhibition on the data presented in this study.
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Recurrence after first seizure
SiR,&mdash;The National General Practice Study of Epilepsy (Nov 24,
p 1271) might leave the casual reader with the impression that the
risk of recurrence after a first seizure is at least 78% within three
years. The study group states that they have largely overcome
selection bias but it is not clear how many patients were referred
immediately after the first event.
The diagnosis "definite epileptic seizures" was made on all
available information, including recurrence pattern, up to 6 months
after the index seizure. What would have been the outcome in
respect of accuracy of diagnosis and risk of recurrence if the
diagnosis had been made immediately after the index seizure? Such
a procedure would seem to be more relevant clinically.
Most patients had had several seizures (9% had had 10 or more)
before they were enrolled. Including these patients (with a
recurrence rate of 100%) in a study of the prognosis after a first
seizure will certainly lead to gloomy results. The risk of recurrence
for patients admitted after the first seizure (46%, group C) is of
more practical importance, and accords with hospital-based
studies.12
This study is of great importance for the epidemiology of epilepsy
but application to clinical practice-for example, on the dilemma
whether or not to start antiepileptic drug treatment after a first
seizure-seems hazardous. The risk of recurrence in patients seen
with a first seizure by a general practitioner or referred to a hospital
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